10-Q: Nika Pharmaceuticals Reports Q2 2026 Results, Faces Going Concern Doubt

Nika Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing net losses and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Summary

• Nika Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $19,694 for the three months ended June 30, 2026, and a net loss of $33,054 for the six months ended June 30, 2026.
• As of June 30, 2026, the company has an accumulated deficit of $9,037,063.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to its lack of revenue and reliance on related party loans.
• The company's cash balance was $2,932 as of June 30, 2026.
• General and administrative expenses were $14,848 for the three months ended June 30, 2026, and professional fees were $4,846.
• The company is involved in various agreements and acquisitions, including exclusive rights for TNG, Carotilen, and Physiolong, and a joint business agreement for IPF platform products.
• A common control merger with Nika BioTechnology, Inc. was completed, increasing ownership in Nika Europe, Ltd. to 80%.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued net losses, significant accumulated deficit, and substantial doubt about its ability to continue as a going concern, despite some strategic acquisitions and agreements.

Positives

• The company has entered into several exclusive rights agreements for the production and distribution of various pharmaceutical products and dietary supplements.
• A joint business agreement was signed to develop medicinal products based on the Inactivated Pepsin Fraction (IPF) platform.
• The company acquired four technologies for generic drugs and a dietary supplement.
• The company's common stock was uplisted to OTCQB on December 9, 2024.
• A consultancy agreement was signed with MD Global Partners, LLC to assist in capital raising and growth initiatives.

Negatives

• The company reported a net loss of $19,694 for the three months ended June 30, 2026, and $33,054 for the six months ended June 30, 2026.
• The company has an accumulated deficit of $9,037,063 as of June 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern due to no revenue and reliance on related party loans.
• Disclosure controls and procedures were found to be not effective, with noted potential material weaknesses in the lack of an audit committee and separation of duties.
• Cash and cash equivalents were only $2,932 as of June 30, 2026.
• The company received $22,000 in loan proceeds from related parties for the six months ended June 30, 2026, down from $45,000 in the prior period.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to its lack of revenue and reliance on related party non-interest bearing loans.
• The company's disclosure controls and procedures were not effective, with potential material weaknesses identified.
• The company has a significant accumulated deficit of $9,037,063 as of June 30, 2026.
• The company's ability to raise additional capital through equity or debt offerings, or borrowings, is uncertain.
• The company is subject to risks associated with its various agreements and acquisitions, including potential integration challenges and market acceptance of its products.

Future Outlook

The company's future outlook is uncertain due to its ongoing net losses and substantial doubt about its ability to continue as a going concern. The company may seek additional capital through equity or debt offerings or borrowings. The company is pursuing various strategic agreements and acquisitions to expand its business operations.

Management Comments

• Management has evaluated the effect of the timing difference in prepaid expense amortization and concluded that it is not material to the previously issued financial statements for the three months ended March 31, 2026.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives.
• The company is glad that it has found a competent accounting firm that has the necessary expertise in both US GAAP and IFRS, which will allow it to cater to the Company's international accounting needs.

Industry Context

StockSavvy.ai notes that Nika Pharmaceuticals operates in a highly competitive and capital-intensive industry. The company's focus on niche products and international expansion through Nika Europe, Ltd. is a common strategy for smaller pharmaceutical firms seeking market access. However, the persistent lack of revenue and significant accumulated deficit are critical concerns that place it at a disadvantage compared to larger, established players.

Comparison to Industry Standards

• The company's net loss of $19,694 for the quarter and $33,054 for the six months, coupled with an accumulated deficit of over $9 million, is significantly worse than industry standards for established pharmaceutical companies which typically aim for profitability or are in advanced stages of clinical development with substantial funding.
• The reliance on related party loans for operating expenses is not a sustainable industry standard; established companies typically rely on equity financing, debt, or operating revenue.
• The lack of an audit committee and separation of duties represents a significant deviation from corporate governance best practices expected in the pharmaceutical industry, where rigorous oversight is paramount.

Corporate Governance

Legal Proceedings

• There are no legal proceedings against the Company and the Company is unaware of any proceedings contemplated against it.

Related Party Transactions

• During the six months ended June 30, 2026, Nika Europe, Ltd. advanced the Company $22,000 for operating expenses. As of June 30, 2026, the total amount due to Nika Europe is $101,460.
• As of June 30, 2026, the total amount due to CEO Dimitar Slavchev Savov is $205,164 for operating expenses.
• As of June 30, 2026, the total amount due to Nika Pharmaceuticals LTD is $34,000 for operating expenses.
• Exclusive Rights Agreements were entered into with VITAL FE Joint Stock Company and MICAR 11 LTD., with preferred stock issued to Dimitar Slavchev Savov.
• Exclusive Rights Agreement with Dimitar Slavchev Savov for six dietary supplements.
• Dimitar Slavchev Savov paid the initial down payment of $191,534 for a vial production line equipment for Nika Europe, Ltd.
• Nika Pharmaceuticals, Ltd. made an in-kind contribution of a production building and land to Nika Europe, Ltd., valued at $2,016,562 USD.
• The acquisition of Nika Pharmaceuticals, Ltd. from Dimitar Slavchev Savov was rescinded.

Stakeholder Impact

• Shareholders: Continued net losses and going concern doubt may negatively impact share value and investor confidence. Potential capital raises could dilute existing shareholdings.
• Creditors: The company's financial instability and reliance on related party loans may raise concerns for creditors regarding repayment.
• Employees: Uncertainty about the company's future could impact employee morale and job security.
• Suppliers: The company's financial condition may affect its ability to meet payment obligations to suppliers.

Next Steps

• The company may seek additional capital through equity or debt offerings or borrowings.
• Nika Europe, Ltd. is preparing the construction of a pharmaceutical factory.
• The company will continue to develop its business through various agreements and acquisitions.

Key Dates

Recommendation

The company exhibits significant financial distress, including ongoing net losses, a substantial accumulated deficit, and explicit doubt about its ability to continue as a going concern. While strategic agreements are in place, they have not translated into revenue or profitability. The lack of effective internal controls further exacerbates the risk. Investors should consider selling their holdings due to the high risk of financial insolvency.

Keywords

pharmaceuticals, biotechnology, drug development, dietary supplements, clinical trials, financial statements, going concern, related party transactions